Advertisement

Issue 26, Volume 128

Cover Figure: Representative CD37+ (red) membranous staining pattern by immunohistochemistry in a specimen from a patient with diffuse large B-cell lymphoma. See the article by Xu-Monette et al.

WASHINGTON, December 29, 2016 – Welcome to “This Week in Blood,” a weekly snapshot of the hottest studies from each week’s issue of Blood, the official journal of the American Society of Hematology (ASH), hand-picked by Blood Editor-in-Chief Bob Löwenberg, MD, PhD, and Deputy Editor Nancy Berliner, MD.

Cost-effectiveness of anticoagulants for suspected heparin-induced thrombocytopenia in the United States
Aljabri and colleagues model institutional costs and average wholesale price to compare the cost-effectiveness of fondaparinux, argatroban, and bivalirudin for treatment of heparin-induced thrombocytopenia. They conclude that fondaparinux offers advantages in terms of both cost and prevention of adverse events.

Screening transplant donors for HTLV-1 and -2
In a Blood Forum, Gallo and colleagues make the case for screening for human T-cell lymphotropic virus type 1 (HTLV-1) and HTLV-2 in potential solid organ donors, citing the risk of rapid development of HTLV-1–associated myelopathy/tropical spastic paraparesis in recipients of organs from asymptomatic carriers.

Protein stabilization improves STAT3 function in autosomal dominant hyper-IgE syndrome
STAT3 mutations are a dominant-negative cause of hyperimmunoglobulin E (hyper-IgE) syndrome (Job syndrome). Bocchini and colleagues describe a novel mechanism by which these mutations act by decreasing STAT3 protein stability and demonstrate partial reversal of the phenotype by agents that increase chaperone protein activity.

Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma
Xu-Monette et al report that expression of CD37 (tetraspanin TSPAN26) is expressed in about 40% of cases of diffuse large B-cell lymphoma(DLBCL), where it is a powerful positive predictor of survival following treatment with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP), trumping other negative prognostic factors.

Targeting BTK through microRNA in chronic lymphocytic leukemia
Although ibrutinib is an extremely effective therapy for chronic lymphocytic leukemia, acquired Bruton tyrosine kinase (BTK) mutations can lead to resistance and relapse with poor outcomes. Bottoni and colleagues describe an alternative novel mechanism for targeting BTK through the use of histone deacetylase inhibitors, which reverse silencing of microRNAs that target BTK.

How I evaluate and treat thrombocytopenia in the intensive care unit patient
Using a series of six patients, Greinacher and Selling describe the wide range of etiologies leading to thrombocytopenia in intensive care unit patients and provide a perspective on their evaluation and management.

Calreticulin exposure by malignant blasts correlates with robust anticancer immunity and improved clinical outcome in AML patients
Fucikova and colleagues demonstrate that high-level suface expression of calreticulin, a damage-associated molecular pattern (DAMP) protein, in acute myeloid leukemia (AML) blasts is associated with a tumor-specific immune response that improves clinical outcomes.

 

This week's complete table of contents

Why Submit to Blood?

 

Blood (www.bloodjournal.org), the most cited peer-reviewed publication in the field of hematology, is available weekly in print and online. Blood is the official journal of the American Society of Hematology (ASH) (www.hematology.org), the world’s largest professional society concerned with the causes and treatment of blood disorders.

ASH’s mission is to further the understanding, diagnosis, treatment, and prevention of disorders affecting blood, bone marrow, and the immunologic, hemostatic, and vascular systems by promoting research, clinical care, education, training, and advocacy in hematology.

blood® is a registered trademark of the American Society of Hematology.